EvoluteIQ, a native AI platform, secured $53 million in minority growth capital from Baird Capital to accelerate global expansion and strengthen its leadership in enterprise-grade agentic AI automation. Baird Capital’s Daina Spedding and Mark Donnelly will join the EvoluteIQ Board of Directors.

Founded in 2019, EvoluteIQ develops the EIQ platform for automating complex business processes. Built on its Agentic Mesh Architecture (aMa) and an AI Workbench, EIQ orchestrates end-to-end workflows across sectors such as banking and financial services, insurance, healthcare, telecommunications, and manufacturing.

The AI-native platform unifies process orchestration, data integration, and generative-AI–assisted decisioning in a single Low-Code/No-Code/Pro-Code environment, replacing fragmented toolchains.

Designed for complex, regulated organisations, EIQ enables teams to design, deploy, and scale AI-enabled business processes with greater speed, security, and cost efficiency. The platform is used by some Fortune 500 enterprises to automate workflows and improve operational resilience.

Sameet Gupte, Co-founder and Chief Executive at EvoluteIQ, commented:

The Agentic AI market represents a fundamental shift from reactive automation to proactive, intelligent orchestration.
Baird Capital’s expertise in scaling technology companies, network, and global resources will help us accelerate our journey as we focus on driving transformative growth through outcome driven agentic models.

This funding will enable the company to accelerate its global expansion and strengthen its leadership in enterprise-grade agentic AI–driven automation.

Warsaw-based HealthTech startup Doctor.One has raised a €4 million Seed round to support expansion into Germany, Spain, and the UK, building on its early commercial success in Poland and demand for chronic care solutions that move beyond episodic or telemedicine models.

The round was led by YZR Capital, with participation from Impact Ventures and existing investors.

“We aim to become the go-to digital companion for healthcare professionals managing chronic patients – keeping them connected, informed, and supported between in-person visits,” said Maciej Malenda, the Co-founder and CEO of Doctor.One.

Founded in 2021, Doctor.One is a chronic care platform that aims to empower healthcare professionals to stay connected with their patients through continuous, asynchronous communication. By transforming care into a relationship-driven experience beyond the visit, the company looks to help improve engagement, boost adherence, and ensure that no chronic patient feels alone in their health journey.

Rather than replacing the physician-patient connection, the platform says they strengthen it – empowering healthcare professionals to support their patients between hospital appointments or clinic visits without overloading their schedules.

The company is currently running programmes with pharmaceutical companies Novartis, Novo Nordisk, Merck and AstraZeneca, helping its partners improve adherence, patient engagement, and long-term outcomes through structured digital care paths and human touch.

With almost half a million of microinteractions facilitated across therapeutic areas such as obesity, oncology, neurology, and endocrinology, the platform has proven both clinically valuable and psychologically resonant.

“We are strong believers in exceptional teams fixing crucial problems on a large scale with innovative solutions,” said Markus Feuerecker, the Co-founder and Managing Partner from YZR Capital. “In Doctor.One we found such a team that stands out with their asynchronous care model and already proven success in tackling key issues in care pathways using scalable technology while providing clear value to patients, providers and pharma groups at the same time.”

Doctor.One is also collaborating with healthcare providers across Europe, including a flagship partnership with Uniwersyteckie Centrum Kliniczne (UCK) in Gdańsk as part of the EU-funded Amber Project. This initiative, uniting partners from five countries, is transforming cancer care through proactive, home-based support that’s relational rather than transactional.

Still in 2025, the company is on the way to increase its revenue eightfold and grow its team in Sales, Product, AI, and Growth to support the expansion with its focus on relational, continuous care.​

“Doctor One is making doctor-patient direct communication more accessible and taking it to a new level, with the aim of providing more effective and more human treatment,” added Gergő Iváncsics from Impact Ventures.

Operating in full compliance with GDPR and ISO standards , the team is now preparing to scale its platform across Germany, Spain and UK —Europe’s largest healthcare markets.

The post Polish health platform Doctor.One secures €4 million to expand its asynchronous care model for chronic patients appeared first on EU-Startups.

Germany-based AI compliance platform Kertos has closed a €14 million Series A to redefine AI-native compliance in Europe. The round was led by global fintech investor Portage, with continued participation from existing backers Pilabs, Redstone, 10x Founders, and seed+speed Ventures.

Kertos is a European compliance engine that pairs a powerful operating system with AI-native automation and on-demand expert support. It integrates with your tech stack, automatically discovers assets, surfaces real-time insights, assesses risk, and automates the end-to-end workflow, from document drafting and evidence collection to continuous monitoring, reducing the time and effort required to stay compliant.

By streamlining repetitive, complex tasks, Kertos’ AI agents make compliance effortless and enable audit readiness in days.

Kertos co-founder Dr. Kilian Schmidt said the company’s OS and AI agents now automate the entire compliance workload, turning compliance into a strategic lever for European businesses. He added that the platform delivers at scale, eliminating busywork, reducing costs, and providing the infrastructure Europe needs to achieve operational excellence and meet leading European and global frameworks.

As Europe’s regulatory landscape grows more complex, Kertos leads with a Europe-first approach, delivering end-to-end compliance, from asset discovery and regulatory mapping to certification and continuous audit readiness, for businesses of every size. Startups and scale-ups get compliant fast to unlock enterprise deals, mid-market firms automate manual work to fuel growth, and large corporates replace fragmented processes with AI so teams can focus on strategy and governance.

Finnish startup Time Atlas Labs, which helps people track and learn from life’s most important moments, has raised €1.8 million in growth funding led by Lifeline Ventures, with participation from a syndicate of angel investors including Duolingo co-founder Severin Hacker and Linear’s Tuomas Artman.

While many apps track parts of life, such as workouts, health metrics, or diet, none capture the full picture or help users learn from past events and patterns. This gap inspired Time Atlas Labs to create Time Atlas, its Active Life Tracking app. The platform builds a private, continuous timeline of a person’s life by linking activities with context, enabling users to revisit experiences and uncover meaningful patterns.

Founded in 2024 by Aapo Kyrölä, Markus Stenberg, and Juho Pennanen, the company was born from Kyrölä’s realisation that he couldn’t remember many key moments from his first year of fatherhood.

Privacy is a central principle for Time Atlas Labs. Unlike other tracking tools, it never shares data with third parties. Users can choose to share information with close contacts, but only on an optional basis.

Time Atlas goes beyond fitness and sleep tracking by creating a private life timeline that connects activities, places, and personal notes, helping people recall and reflect on meaningful experiences.

Various types of life tracking have been around for years, but they’ve always been segmented to specific activities. What we’re building at Time Atlas Labs takes all of these moments and lets people see connections between their actions and use them to understand themselves,

said Aapo Kyrölä, CEO and co-founder.

The health and wellness tracking market is projected to more than triple by 2034, while life tracking overall has surged in recent years, largely through sports and sleep technologies.

Time Atlas Labs represents the next evolution of this space, offering a single platform that maps an entire life of activities and enriches them with comments and journal entries that bring depth and context to each moment.

The new funds will be used to further develop and grow its Active Life Tracking app, Time Atlas.

Belgian company SEQUESTO, a scale-up transforming how organisations handle tenders, RFIs, and RFPs, has secured a strategic €2.5 million investment from Smartfin and Newion.

Founded in 2020, SEQUESTO is an AI-first platform that uses agentic workflows to automate repetitive, error-prone tasks across the entire RFx lifecycle, thereby enhancing tender teams’ efficiency and win rates.

As tenders grow in number and complexity, and AI breakthroughs emerge, the global market for RFP optimisation software is accelerating. Yet for most organizations, responding to RFPs, RFIs, and other complex procurement procedures remains largely manual, slow, and costly, with frustratingly low win rates.

Unlike legacy players that deliver only incremental improvements, SEQUESTO reimagines the entire RFx lifecycle with advanced AI, setting a new standard in the market. Its impact extends well beyond time savings, as SEQUESTO consistently reduces content management costs, accelerates time to value, and improves win rates on complex bids.

Now an international scale-up, SEQUESTO operates across key European markets and the United States, serving fast-growing SaaS firms and highly regulated enterprises alike.

The new funding will support SEQUESTO’s international expansion and further develop its market position.

London’s BNVT Capital today announced the launch of its debut €126 million fund to invest in AI-first and technology-driven companies “solving humanity’s most pressing challenges“.

Rory Mounsey-Heysham, managing partner at BNVT Capital said: “LPs and entrepreneurs are crying out for investors who see the world’s biggest challenges not as a moral quandary, but as vast untapped markets. A big problem is simply a big market waiting to be served.”

BNVT Capital is a global VC firm, launched by investors previously at the Gates Foundation, Hedosophia and Goldman Sachs. With a presence in London, New York, and Riyadh, the global investment team is guided by the principle of Benevolent Disruption, an idea backed by proprietary returns data, that solving Big Problems is Big Business.

BNVT Capital was founded by Managing Partners Rory Mounsey-Heysham (ex-Gates Foundation), and Chris Corbishley (ex-Hedosophia).

Their approach is built on the study, “Benevolent Disruption: The Fortune in Solving the World’s Biggest Problems”, co-authored with Professor Josh Lerner of Harvard Business School and VenCap International PLC (a large VC allocator) and academics at MIT and Oxford University.

Drawing on proprietary data on 500+ VC funds and 14,000 companies, over the last 40 years, the study unveiled an enormous, and reportedly undiscovered, source of investment value: just 30% of venture-backed companies tackle big problems and these have historically delivered 51% higher returns compared to their peers.

Chris Corbishley, managing partner at BNVT Capital said: “Investors have missed a striking pattern in their own data. For too long, investors have been backing fads, not needs – distracted by incremental technologies making life marginally faster, cheaper, or easier. Venture capital is about swinging for the fences – backing solutions that can reshape society for the better. That is what Benevolent Disruption is about.”

The fund has already invested in 11 companies across Europe and the US, including Swap Commerce (UK), Cloover (Germany), and Dawnguard (Netherlands), co-investing alongside global firms such as TPG, Iconiq, Lowercarbon, and QED.

The fund’s origins came from Mounsey-Heysha seeing the outsized returns Bill Gates was generating from investing in solutions to global problems, and then Corbishley seeing the same pattern play out in his own portfolio at Hedosophia.

The VC says this new fund and investment concept comes at an interesting time when politicians and the investor community alike are at war as to the role of business in society. BNVT Capital position their thesis as a ‘third way’ between the ESG antithesis and unfettered capitalism.

Barry Sternlicht, CEO of Starwood Capital, added: “The greatest economic value comes from investing in mission-driven brands that don’t just follow the market – they redefine it.”

The fund’s thesis has attracted support from leading entrepreneurs and investors, including founders and leaders at Shopify, Google, Octopus Energy, Remitly, and institutional support from Starwood Capital, Investcorp, TPG, and others.

BNVT portfolio Founder Sam Atkinson, Founder of Swap Commerce, said: “BNVT has been pivotal in rapidly scaling Swap through strategic capital and deep expertise. Their global industry insights have directly shaped our growth strategy and product evolution.”

While Jodok Betschart, Founder of Cloover, said: “BNVT has been a fundamental partner in accelerating Cloover’s growth, unlocking over $100 million in funding capacity and connecting us with world-class climate investors. Their deep expertise in climate tech has been instrumental.”

BNVT Capital plans to expand its portfolio to 25–30 companies globally in the coming two years, continuing to prove that solving the world’s biggest problems provides one of the most lucrative opportunities in venture investing.

The post Former Gates Foundation investors launch €126 million VC fund BNVT Capital to solve “the biggest problems” appeared first on EU-Startups.

BNVT Capital today announced the launch of its debut $150M fund to invest in AI-first and technology-driven companies solving humanity’s most pressing challenges.

BNVT’s approach is built on a groundbreaking study, “Benevolent Disruption: The Fortune in Solving the World’s Biggest Problems”, co-authored with Professor Josh Lerner of Harvard Business School and VenCap International PLC (a large VC allocator) and academics at MIT and Oxford University. 

Drawing on proprietary data on 500+ VC funds and 14,000 companies, over the last 40 years, the study unveils an enormous source of investment value: just 30 per cent of venture-backed companies tackle big problems and these have historically delivered 51 per cent higher returns compared to their peers.

BNVT Capital was founded by Managing Partners Rory Mounsey-Heysham (ex-Gates Foundation), Chris Corbishley (ex-Hedosophia), as well as Co-Founder Nasir Alsharif (Chairman of Sackville Capital). Sackville Capital is a London-based private markets investor and seeded BNVT Capital. 

The funds' origins stemmed from Rory observing the outsized returns Bill Gates was generating from investing in solutions to global problems, and then Chris witnessing the same pattern play out in his own portfolio at Hedosophia. 

The fund has already invested in 11 companies across Europe and the US, including Swap Commerce https://www.swap-commerce.com/ (UK), Cloover (Germany), and Dawnguard (Netherlands), co-investing alongside global firms such as TPG, Iconiq, Lowercarbon, and QED.

Rory Mounsey-Heysham, managing partner at BNVT Capital, said:  

“LPs and entrepreneurs are crying out for investors who see the world’s biggest challenges not as a moral quandary, but as vast untapped markets. A big problem is simply a big market waiting to be served.”

Nasir Alsharif, co-founder of BNVT, added: 

“This is truly a differentiated investment thesis - backed up by extraordinarily real-world data. Myself, and Sackville Capital, were excited by the countercyclical nature of the thesis - creating outsized returns from solving the biggest problems.”

Chris Corbishley, managing partner at BNVT Capital, said:

“Investors have missed a striking pattern in their own data. For too long, investors have been backing fads, not needs - distracted by incremental technologies making life marginally faster, cheaper, or easier.

Venture capital is about swinging for the fences—backing solutions that can reshape society for the better. That is what Benevolent Disruption is about.”

The fund’s thesis has garnered support from leading entrepreneurs and investors, including founders and leaders from Shopify, Google, Octopus Energy, and Remitly, as well as institutional backing from Starwood Capital, Investcorp, TPG, and other prominent investors.

As part of the announcement, BNVT Capital is launching the Benevolent Disruption platform and community. 

BNVT Capital plans to expand its portfolio to 25–30 companies globally in the coming 2 years, continuing to prove that solving the world’s biggest problems provides one of the most lucrative opportunities in venture investing.

Lead image: Chris Corbishley and Rory Mounsey Heysham. Photo: uncredited.

suena energy, a technology company specialising in algorithmic optimisation and trading for energy storage systems and renewable energies, has successfully closed an €8 million Series A funding round. 

suena energy’s proprietary Energy Trading Autopilot enables fully automated, AI-driven trading of flexibilities across all relevant power and ancillary service markets. 

Using real-time data and forecasts, the platform generates optimal dispatch schedules to maximise revenues while minimising risk and battery degradation.

A key focus of the growth strategy is the rapidly expanding market for co-located storage. These projects not only offer operational synergies and new revenue models but also require strong technological, regulatory, and economic integration. suena energy addresses this complexity with a software approach that can flexibly adapt to market and project conditions, helping customers to develop storage projects quickly, efficiently, and profitably – for a resilient, decentralised, and decarbonised power system.

Dutch energy company Eneco led the round through its investment arm Eneco Ventures. It was joined by impact venture capital fund InnoEnergy and existing investors InnoEnergy, J.O.S.S., Santander, and Energie 360°. 

“This funding round marks a strategic milestone for us, enabling us to take our business model to the next level – with strong partners at our side who share our vision”, said Lennard Wilkening, PhD, Co-Founder and CEO of suena energy.

“Eneco Ventures and 4impact are highly complementary to our existing investor base. Their strategic-operational and digital technology expertise brings us closer to our goal of becoming a leading provider of intelligent flexibility trading in Europe.”

Till Wyszynski, Investment Director at Eneco Ventures, shared:

“suena energy impressed us with its outstanding team, innovative trading platform, and clear vision.

The ability to optimise complex assets like the combination of renewables and storage in real time is a crucial element of the energy transition. suena energy has the potential to become a market leader in this space.”

According to Pauline Wink, Managing Partner and Co-Founder of 4impact capital:

“We are deeply impressed by Suena Energy’s focus on optimising co-located storage and renewable energy – an increasingly vital component of the energy transition – as well as the strength and complementarity of its founding team. 

The team has secured key customers, developed clear growth plans, and achieved significant progress.”

suena energy will use the fresh capital to strengthen its position in the rapidly growing energy storage market, with a focus on international expansion, scaling its business model, and optimising the co-location of storage systems with renewable energy assets. 

Lead image: suena energy. Photo: uncredited. 

Hamburg-based suena energy has raised an €8 million Series A round to boost its presence in the fast-growing energy storage sector, focusing on international expansion, scaling its business model, and optimising the co-location of storage with renewable energy assets.

The round was led by Dutch energy company Eneco through its investment arm Eneco Ventures and joined by impact venture capital fund 4impact capital. Existing investors InnoEnergy, J.O.S.S., Santander, and Energie 360° also participated.

suena energy is a fully algorithmic, AI-driven provider of trading optimisation for battery storage and renewable assets. Its proprietary Energy Trading Autopilot ingests real-time data and forecasts to generate optimal dispatch schedules and execute fully automated trades across power and ancillary service markets, lifting revenues, extending battery life by minimising degradation, and reducing risk.

The offering also covers optimised marketing for standalone storage, co-located solar and wind projects, direct renewable marketing, portfolio optimisation, and white-label partner solutions.

A core growth focus is co-located storage, an expanding segment with operational synergies and new revenue models that also demand tight technological, regulatory, and economic integration.

suena energy addresses this complexity with adaptable software that fits market and project conditions, enabling customers to develop and operate storage projects faster, more efficiently, and more profitably, supporting a resilient, decentralised, and decarbonised power system.

This funding round marks a strategic milestone for us, enabling us to take our business model to the next level – with strong partners at our side who share our vision,

said Lennard Wilkening, PhD, Co-founder and CEO of suena energy.

Eneco Ventures and 4impact  are highly complementary to our existing investor base. Their strategic-operational and digital technology expertise bring us closer to our goal of becoming a leading provider of intelligent flexibility trading in Europe.

With this funding, the company will expand abroad, scale its model, and prioritise co-located storage projects, a rapidly growing area of the energy transition.

CoreWeave and Salesforce are the latest US tech firms to pledge significant AI investments into the UK, which are coinciding with President Trump’s visit to the UK.

CoreWeave, which provides cloud computing services to companies building AI models, today announced the next $1.5bn phase of its £2.5bn investment in AI data centre capacity and operations in the UK.

CoreWeave says its investment will provide AI labs, enterprises, the public sector, research institutions and startups with AI infrastructure. It also said it will help create jobs across engineering, operations and related services.

“Our investment in the UK will establish one of the world’s largest concentrations of state-of-the-art, sustainable compute, unlocking new opportunities for innovation, economic growth, and scientific discovery,” said Michael Intrator, co-founder, chairman and CEO of CoreWeave.

As part of this investment, CoreWeave is partnering with Nvidia and DataVita, the Scottish data centre firm, in Scotland, which will deploy Nvidia GPUs, which are backed by” entirely by renewable energy, and leveraging state-of-the-art closed-loop cooling technology to minimise water consumption”.

In January this year, CoreWeave opened its first two data centres in the UK, the first outside of its native US. The US tech firm opened its European HQ in London in 2023.

Meanwhile, US software giant Salesforce, whose UK arm axed more than 450 jobs in 2024, said it is increasing its investment to $6bn in its UK business through to 2030. This marks an extension of Salesforce's $4bn five-year investment in 2023 in the UK.

Salesforce’s investment includes the UK becoming its AI hub for Salesforce UK and Europe, with new R&D teams, a previous $4 billion commitment, and the establishment of its first AI Centre in London. It is also investing in UK companies that are building in AI.

“We are doubling down on our long-standing commitment to the UK with this significant investment,” said Marc Benioff, chair and CEO, Salesforce.

Salesforce has operated in the UK for around 25 years. Google has also announced a significant investment in UK AI, with OpenAI and Nvidia also expected to confirm investments.

Valencia’s Highlight Therapeutics, a biopharmaceutical company focused on the development of next-generation immunotherapies, has raised €15 million aimed at strengthening their position in the treatment of skin tumours and accelerating its clinical development plan.

The funds were raised in part by Buenavista Equity Partners, through its specialised fund BV Healthcare Growth Innvierte I (BHG I), created in collaboration with Columbus Venture Partners.

Marisol Quintero, CEO of Highlight Therapeutics, said: “Buenavista’s investment enables us to strengthen our team and consolidate our position as a leading company in the development of treatments for skin tumours.” 

Founded in 2013, Highlight Therapeutics is a BioTech company specialising in immuno-oncology, focused on developing innovative cancer therapies. Its investigational compound, BO-112, is a double-stranded RNA immunotherapy allegedly capable of powerfully activating the immune system and enhancing the response to tumours.

In collaboration with the Spanish National Cancer Research Center (CNIO), the company is conducting clinical trials in various hospitals.

Buenavista’s investment will enable Highlight to advance its lead compound, BO-112, which is currently in a Phase 2b clinical trial for the treatment of basal cell carcinoma – the most common cancer, with over six million cases across the EU and the US. The treatment has reportedly already demonstrated efficacy against aggressive melanoma tumours, and the current study will allow its use to be extended to other tumour types.

BO-112, a derivative of BO-110, is a compound discovered in 2009 by Marisol Soengas’s group at the CNIO and represents the institution’s first oncology candidate to reach clinical studies in patients. The compound works by mimicking a viral infection, activating the immune system to target tumour cells across various types of cancer, including those resistant to immunotherapy.

The company is also announcing the appointment of Abel Riera, who has extensive experience in Business Development and M&A, as Chief Business Officer as part of its strategy to reinforce its executive team, with plans of further additions in the near future.

Nuria Osés, Managing Partner of Healthcare Growth at Buenavista, commented: “Highlight’s strategy is fully aligned with BHG I’s vision of supporting therapies with high transformative potential, a strong scientific foundation, and a clear focus on specific medical needs. Its collaboration with leading institutions such as the CNIO and its commitment to developing accessible treatments further strengthen the project’s credentials. We are very excited to support them in this new phase.”

The transaction announced today marks the third investment by the BV Healthcare Growth Innvierte I fund, following its participation in Syngoi, a CDMO specialised in synthetic DNA manufacturing, and Quibim, a pioneer in transforming precision medicine through imaging biomarkers powered by artificial intelligence

The post Spanish cancer startup Highlight Therapeutics closes €15 million round to further skin tumour treatment appeared first on EU-Startups.

Enhanced Genomics, a British BioTech company innovating 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has completed a financing round, extending its total Series A funding to €16 million.

Investors in this latest funding are BGF, Parkwalk and Meltwind.

“Our Founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies.” said Dietrich A. Stephan, Ph.D., Chair, Enhanced Genomics.

Founded in 2020, Enhanced Genomics claims to be the only BioTech company able to define causal biology from disease-associated variants on a genome-wide scale, enabling the rapid identification of new, high-confidence, first-in-class therapeutic targets for common diseases, with blockbuster potential.

Unlocking decades worth of genetic data and providing unparalleled validation via its proprietary 3D multi-omics platform and data-rich human cell type-specific atlas, the Company is able to expedite drug discovery and precision medicine.

Enhanced’s 3D multi-omics platform is the only genome-wide, hypothesis-free technology able to translate massive amounts of disease-associated variant data into causal biology on a cell-type-specific basis. According to the company, this approach supports both target prioritisation, more than doubling the probability of success, and target identification, vastly increasing the number of novel disease targets that can be identified, more efficiently and in a fraction of the time previously possible.

It also allows the stratification of patients into responder groups to improve and accelerate clinical trials. 

“This puts us in a strong position to lead the next major shift in pharma. When developing a novel approach to drug discovery, clarity of thought and courage are required to build deep conviction, and we are proud to have built a team that embodies this. We thank our investors for continuing to support our vision,” added Stephan.

The funding will be used to expand Enhanced’s internal therapeutic pipeline in common diseases, including autoimmune conditions such as inflammatory bowel disease. The latest investment will enable the Company to scale its output through strategic partnerships with pharma and biotech, leveraging novel target identification and asset-based opportunities to drive long-term growth.

By translating massive amounts of disease-associated data into actionable insights, Enhanced is identifying high confidence targets with strong genetic evidence of causality, increasing the probability of success in pharmaceutical development, and in a fraction of the time and cost previously possible.

The post Cambridge’s Enhanced Genomics extends funding to €16 million to drive development of therapeutics pipeline appeared first on EU-Startups.

Workday, the enterprise AI platform for managing people, money, and agents, has entered into a definitive agreement to acquire Sana, a Stockholm AI company building the next generation of enterprise knowledge tools. Since its founding in 2016, Sana has developed intuitive workplace tools that elevate humans with AI.

Sana’s core products, Sana Learn and Sana Agents, have already served over one million users across hundreds of enterprises. In addition to powering a new Workday experience, Sana will continue to develop Sana Learn and Sana Agents. As part of Workday, Sana will be able to accelerate its growth and deliver even more innovation to its customers at scale.

“Sana’s team, AI-native approach, and beautiful design perfectly align with our vision to reimagine the future of work,” said Gerrit Kazmaier, president, Product & Technology at Workday.  

“This will make Workday the new front door for work, delivering a proactive, personalised, and intelligent experience that unlocks unmatched AI capabilities for the workplace.”

“Our focus has always been on creating intuitive AI tools that improve how people learn and work,” said Joel Hellermark, founder and CEO of Sana.  

“I’m excited to bring these tools to 75 million Workday users and partner with Workday’s iconic team to launch a new era of superintelligence for work.”

With Sana, Workday will create the work experience of the future, where enterprise knowledge, data and actions converge into one. Leveraging Workday’s unique data and context around people and money — as well as a rich ecosystem of builders and partners — the employee experience will become personalised and proactive, better anticipating employee needs based on their role, team, and projects. 

For example, hiring managers will be able to generate tailored dashboards to monitor their live recruitment pipeline, automate the end-to-end performance review process, and receive proactive suggestions on onboarding new hires based on real-time performance data.

The transaction is expected to close in the fourth quarter of Workday’s fiscal year 2026, ending January 31, 2026, subject to the satisfaction of customary closing conditions.

Early-stage investment firm Anthemis and Cambridge AI Venture Partners (CAIVP), as well as a team comprised of industry experts Sir Andy Hopper, Prof Rob Mullins, Dr Gavin Ferris and Mike Halsall, today announce the launch of CommonAI, a collaborative engineering and computing platform for AI-enabled start-ups, enterprises, engineers, academics and investors.

CommonAI combines the deep AI knowledge of CAIVP with the investment expertise of Anthemis to turbocharge the UK and European AI innovation ecosystem. 

It seeks to tackle the key challenges and barriers startups and enterprises face, allowing them to innovate safely and cost-effectively, reduce their reliance on Big Tech and secure the strategic investment critical to seizing the AI growth opportunity.

Through CommonAI membership, AI-enabled start-ups and enterprises will gain access to world-class IP, including models, weights, framework software, training data and hardware designs, while also gaining affordable access to critical GPU resources.

Together, these capabilities will allow UK and European businesses to develop AI-enabled propositions that can successfully compete at a global scale.

At the heart of the initiative is a non-profit engineering organisation – Common AI CIC – a UK community interest company that will co-develop foundational AI IP in partnership with its members.  The platform additionally provides access to CommonAI Compute Ltd – a facilitator of cost-effective GPU resource. 

Both entities will be underpinned by a shared Digital Commons repository, providing world-class resources to ecosystem members under time embargo.

According to Dr Gavin Ferris, CEO, CommonAI CIC, increasingly, AI startups and SMEs find themselves unable to assemble the computing power, technology and strategic resources necessary to successfully compete on the world stage:

“CommonAI’s innovation platform, shared IP and industry expertise will play a critical role in levelling this playing field, unlocking new growth opportunities and protecting the long-term economic future of both the UK and Europe.

‘Structuring and governing our engineering organisation as an unconflicted Community Interest Company (CIC) ensures that the interests of our members are protected while encouraging collaboration and maximising the potential of the UK AI ecosystem.’

Sir Andy Hopper, Board Chair, CommonAI CIC contends that with Big Tech’s dominance over large-scale AI models and infrastructure, startups are being denied access to this burgeoning opportunity – and even larger enterprises face the challenge of balancing their innovation agenda with the resources required to power their core business:

“By enabling ‘Virtual BigCos’ and unleashing the latent power of our entrepreneurs – and working in partnership with leading engineering talent, research institutions and universities – businesses of all scales in our economy can access the capabilities and expertise they need to thrive on the global stage.”

Following the launch of the CommonAI platform, Anthemis intends to raise a “High Assurance AI” fund to invest in UK and European startups that are applying AI in highly regulated and complex industries such as financial services, healthcare, critical infrastructure and defence. 

This is the first in a planned series of CommonAI-branded funds that aim to extend the traditional VC offering by providing portfolio companies access not only to capital but also to the transformative technology support of the foundational CommonAI platform.

According to Anthemis Founder and Group CEO, Amy Nauiokas, the platform offers a space around which stakeholders can coalesce to deliver meaningful impact. 

“We are building an AI ecosystem to drive forward action – one that clears the barriers to accessing the opportunities presented by a new wave of innovation and combines deep expertise, cutting-edge technology, cheaper compute and access to smart, supportive capital.

Getting this right is critical to the UK and Europe’s economic future and we’re excited about the prospect of working alongside our partners and members to build the next generation of industry champions.’

Romanian-founded startup DRUID AI today announced it has secured $31 million in Series C financing to advance the global expansion of its enterprise-ready agentic AI platform under the leadership of its new CEO, Joseph Kim. 

DRUID AI is an end-to-end enterprise agentic AI platform that enables rapid development and deployment of AI Agents to automate business processes and enhance access to enterprise knowledge.

DRUID Agents deliver personalised, secure, and omnichannel experiences while seamlessly integrating with existing systems, apps, and RPA technologies—empowering businesses to operate smarter, faster, and more efficiently. Founded in 2018, DRUID AI has powered over one billion conversations across more than 4,000 AI Agents and supports 300+ clients globally.

“This investment is both a testament to DRUID AI’s success and a catalyst to elevate businesses globally through the power of agentic AI,” said Kim. 

“Customer success is what it’s all about, and delivering real business outcomes requires understanding companies’ pain points and introducing innovations that help those customers address their complex challenges.

That’s the DRUID AI way, and now we’re bringing it to the world through this new phase of global growth.”

Cipio Partners led the investment, with participation from TQ Ventures, Karma Ventures, Smedvig, and Hoxton Ventures.

Roland Dennert, managing partner at Cipio Partners, explained:

“DRUID AI aligns perfectly with our investment strategy – offering a differentiated, AI-based product in a vast and rapidly growing market. 

Our investment will help accelerate DRUID AI’s expansion into the US and elsewhere, fuel further technological advancements, and strengthen its position as a global leader in enterprise AI solutions.” 

Kim has more than two decades of operating executive experience in application, infrastructure, and security industries. Most recently, he was CEO of Sumo Logic. He serves on the boards of directors of SmartBear and Andela. In addition, he was a senior operating partner at private equity firm Francisco Partners, CPTO at Citrix, SolarWinds, and Hewlett Packard Enterprise, and chief architect at GE.

DRUID AI is trusted by more than 300 global clients across banking, financial services, government, healthcare, higher education, manufacturing, retail, and telecommunications. Leading organisations such as AXA Insurance, Carrefour, the Food and Drug Administration (FDA), Georgia Southern University, Kmart Australia, Liberty Global Group, MatrixCare, National Health Service, and Orange Auchan have adopted DRUID AI to redefine the way they operate.

Genoskin, a Contract Research Organisation (CRO) developing ex vivo human skin platforms capable of testing injected drugs and implanted medical devices, today announces it has raised $8.7 million in its first funding round.

Genoskin provides a scalable and sustainable alternative to animal testing.

By leveraging donated human skin and its proprietary preservation technology, the company provides live immunocompetent *ex vivo *platforms that remain viable for up to seven days post-surgery, enabling more predictive, human-relevant testing than traditional animal or engineered models. 

The models generate large-scale datasets through multiomics approaches, which are further analysed using AI and advanced bioinformatics to deliver meaningful insights into the toxicity and efficacy of tested products in humans. 

Backed by a robust IP portfolio, an established tissue sourcing network and a proven scalable service model, Genoskin’s solutions deliver translational human-relevant insights that improve predictability and regulatory acceptance. 

This combination gives Genoskin a unique competitive advantage in supplying biopharma, cosmetics and cell and gene companies with models that reflect human physiology, especially for skin-related delivery routes such as injectables, including vaccines and topically administered therapeutics.

OCCTE (FPCI Occidev Impacts) led the investment round, alongside Captech Santé, GSO Innovation and CA Toulouse 31 Initiatives. It includes 5.4 million in equity investment and with $3.3 million (€3M) in non-dilutive financing in structured bank debt, provided by Bpifrance and local banking partners: BNP Paribas, Caisse d’Epargne Midi-Pyrénées and Crédit Agricole.

“As a company built on ethical innovation, we are proud to offer sustainable, human-relevant alternatives to animal testing. This investment validates our strategy and reinforces our position as a leader in predictive immunotoxicology using live human skin models,” said Pascal Descargues, Ph.D., CEO of Genoskin.  

“With the support of our investors, Genoskin is well-positioned to drive meaningful change in how biotherapies are developed, ultimately bringing safer treatments to patients worldwide.”

“We are proud to support Genoskin, a company that perfectly embodies our mission to invest in local innovators delivering sustainable solutions with global reach. Genoskin’s technology offers an ethical, scalable alternative to animal testing and pursues a growth strategy that aligns strongly with our values of economic resilience and scientific impact,” said Julien Gomis, managing partner at OCCTE. “

Captech Santé is pleased to contribute to the financing of Genoskin, a company capable of setting new global standards in the development of injectable drugs and that already counts most major global pharmaceutical companies among its clients,” added Alexandre Demailly, investor at Captech Santé. As part of this round, Genoskin welcomes to its Board of Directors: Julien Gomis (OCCTE), Alexandre Demailly (Captech Santé), Emmanuelle Ostiari (OCCTE), and Anaïs Raluy (GSO/CAT31i).

The financing will drive Genoskin’s next phase of growth and support further staff recruitment, with a view to doubling the size of the company within the next three years and to expanding Genoskin’s commercial presence in key global markets. This will include new strategic hires in Europe and Asia by 2026.

Genoskin plans to launch new immune-centric service offerings by 2027 and strengthen its scientific and regulatory leadership with the development of biosimulation platforms and novel human immune models to reduce reliance on animal testing.

Genoskin will also scale up operations through industrial automation and increased production capacity in both the US and France, by moving into its two updated and expanded facilities - in Salem, MA, in 2026 and in Toulouse, France, in 2027. This will double the production of skin models and launch the production of fresh human primary mast cells for next-day delivery in the US.

Lead image: Freepik.

Bucharest-based DRUID AI today announced it has secured €26 million in Series C financing to advance the global expansion of its enterprise-ready agentic AI platform under the leadership of its new CEO, Joseph Kim.

The strategic investment – which will advance DRUID AI’s mission to empower companies to create, manage, and orchestrate conversational AI agents – was led by Cipio Partners, with participation from TQ Ventures, Karma Ventures, Smedvig, and Hoxton Ventures.

“This investment is both a testament to DRUID AI’s success and a catalyst to elevate businesses globally through the power of agentic AI,” said Joseph Kim. “Customer success is what it’s all about, and delivering real business outcomes requires understanding companies’ pain points and introducing innovations that help those customers address their complex challenges. That’s the DRUID AI way, and now we’re bringing it to the world through this new phase of global growth.”

Founded in 2018, DRUID AI is an end-to-end enterprise agentic AI platform that enables rapid development and deployment of AI Agents to automate business processes and enhance access to enterprise knowledge. It has reportedly powered over one billion conversations across more than 4,000 AI Agents and supports 300+ clients globally.

With expertise in banking, financial services and insurance (BFSI), DRUID AI serves industry leaders such as Liberty Global, AXA, Auchan, Muller Medien, and BCR – Erste Group.

In parallel, DRUID AI delivers solutions across education, healthcare, higher education, retail, and telecom for global brands including Carrefour, NHS, Orange, and Kmart Australia.

Roland Dennert, managing partner at Cipio Partners, a premier global venture capital fund, explained: “At Cipio Partners, we focus on supporting growth-stage technology companies that have achieved product-market fit and are ready to scale. DRUID AI aligns perfectly with our investment strategy – offering a differentiated, AI-based product in a vast and rapidly growing market.

“Our investment will help accelerate DRUID AI’s expansion into the U.S. and elsewhere, fuel further technological advancements, and strengthen its position as a global leader in enterprise AI solutions. We are excited to partner with DRUID AI on its journey and look forward to supporting the company in shaping the future of enterprise AI-driven interactions.”

The appointment of Kim as CEO and the new funding come on the heels of DRUID AI earning a Challenger spot in the Gartner Magic Quadrant for Conversational AI Platforms for 2025.

In 2024, DRUID AI grew ARR 2.7x year-over-year. Its platform has powered morethan 1 billion conversations across thousands of agents. In addition, the DRUID AI global partner ecosystem has attracted industry giants Microsoft, Genpact, Cognizant, and Accenture.

DRUID AI Co-founder and Chief Operating Officer Andreea Plesea, who had been interim CEO, commented: “I am delighted Joseph is taking the reins as CEO to drive our next level of growth. His commitment to customer success and developing the exact solutions customers need is in total sync with the approach that has fueled our progress and positioned us to raise new funds. Joseph and the Series C set up DRUID AI and our clients for expanded innovation and impact.”

Powered by advanced agentic AI and driven by the DRUID Conductor, its core orchestration engine, the DRUID platform aims to enable businesses to deploy AI agents and intelligent apps that streamline processes, integrate with existing systems, and fulfil complex requests efficiently. DRUID AI’s end-to-end platform allegedly delivers 98% first response accuracy.

“At Georgia Southern, we recognised that to truly meet the needs of today’s digital native students, we needed to offer dynamic and accurate real-time support that would solve their issues on the spot,” said Ashlea Anderson, CIO at Georgia Southern University. “By leveraging DRUID AI’s platform, we’ve created personalised and intuitive experiences to support students throughout their academic journeys, increasing enrollment and student retention. The result is a more efficient, connected campus where students feel supported, engaged, and better positioned to succeed.”

The post Romanian startup DRUID AI raises €26 million to accelerate agentic AI platform growth under new CEO appeared first on EU-Startups.